By Rebecca Marli,
Project Weight Loss staff writer
October 13, 2007A new weight loss drug called HistaleanTM based on betahistine is believed to quell the cravings for fatty foods, and may have pronounced beneficial effects among women in particular.
The drug is developed by Dr. Nir Barak at the Tel Aviv University Sackler School of Medicine in conjunction with Obecure drug company. Betahistine is an approved drug for the treatment of vertigo and marketed worldwide for over thirty years.
Betahistine blocks the H1 and H3 receptors in the brain, receptors connected to the sense of fullness and craving for fatty products. This drug is safe and used for the treatment of over 100 million people who suffer from dizziness or vertigo.
A clinical trial conducted in the U.S. showed that women who took Histalean for three months managed to lose seven times the weight of women who were following a placebo treatment. What is more important is that none of the participants, males or females, did not complained of any serious side effects.
Weight loss drugs on the market usually have serious side effects. Although they may help someone lose weight, the result may also bring depression or even suicide, according to Dr. Barak.
The results are based on a study that involved overweight people across the U.S. during a twelve week treatment period. The group of women who followed a treatment with high doses of Histalean lost almost three percent of their weight while women in the placebo group lost only 0,4 percent.
The new weight loss drug may be used with anti-psychotic drugs which lead to extreme weight gain for mental health patients. Always talk to a specialist before taking any weight loss pill.
©2007
Project Weight Loss. All rights reserved.
